Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma
- 43 Downloads
Osteosarcoma (OS) is an aggressive malignant tumor of the bones. Our study intended to identify and analyze potential pathogenic genes and upstream regulators for OS. We performed an integrated analysis to identify candidate pathogenic genes of OS by using three Gene Expression Omnibus (GEO) databases (GSE66673, GSE49003 and GSE37552). GO and KEGG enrichment analysis were utilized to predict the functional annotation and potential pathways of differentially expressed genes (DEGs). The OS-specific transcriptional regulatory network was established to study the crucial transcriptional factors (TFs) which target the DEGs in OS. From the three GEO datasets, we identified 759 DEGs between metastasis OS samples and non-metastasis OS samples. After GO and KEGG analysis, ‘cell adhesion’ (FDR = 1.27E-08), ‘protein binding’ (FDR = 1.13E-22), ‘cytoplasm’ (FDR = 5.63E-32) and ‘osteoclast differentiation’ (FDR = 0.000992221) were significantly enriched pathways for DEGs. HSP90AA1 exhibited a highest degree (degree = 32) and was enriched in ‘pathways in cancer’ and ‘signal transduction’. BMP6, regulated by Pax-6, was enriched in the ‘TGF-beta signaling pathway’. We indicated that BMP6 may be downregulated by Pax-6 in the non-metastasis OS samples. The up-regulated HSP90AA1 and down-regulated BMP6 and ‘pathways in cancer’ and ‘signal transduction’ were deduced to be involved in the pathogenesis of OS. The identified biomarkers and biological process in OS may provide foundation for further study.
KeywordsOsteosarcoma Transcription factors DEGs Integrated analysis
CY and XS designed and performed the train of thought, DH and CM analyzed the resulting data, JR, LF, CC and BL contributed the analysis tools. All authors read and approved the final manuscript.
Compliance with Ethical Standards
Ethics Approval and Consent to Participate
Consent to Publication
All authors consented to publication.
All authors declare that they have no conflicts of interest.
- 1.Zhou W, Hao M, Du X, Chen K, Wang G, Yang J (2014) Advances in targeted therapy for osteosarcoma. Discov Med 17(96):301–307Google Scholar
- 2.Bernardini, G., Geminiani, M., Gambassi, S., Orlandini, M., Petricci, E., & Marzocchi, B., et al. (2017). Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma. J Cell PhysiolGoogle Scholar
- 3.Yan H, Zhang B, Fang C, Chen L (2018) Mir-340 alleviates chemoresistance of osteosarcoma cells by targeting zeb1. Anti-Cancer Drugs:1Google Scholar
- 8.Diao C, Xi Y, Xiao T (2018) Identification and analysis of key genes in osteosarcoma using bioinformatics. Oncol Lett 15(3):2789–2794Google Scholar
- 10.Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc 57(1):289–300Google Scholar
- 17.Coskunpinar E, Akkaya N, Yildiz P, Oltulu YM, Aynaci E, Isbir T, Yaylim I (2014) The significance of hsp90aa1, hsp90ab1 and hsp90b1 gene polymorphisms in a turkish population with non-small cell lung cancer. Anticancer Res 34(2):753–757Google Scholar
- 19.Mckay, W., Boden, S., & Yoon, S. (2006). METHODS OF INDUCING THE EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) AND TRANSFORMING GROWTH FACTOR-beta-PROTEINS (TGF-betas) IN CELLS. CA, EP1629106Google Scholar
- 21.Shi, Y. J., & Pan, X. T. (2016). Bmp6 and bmp4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-hjv. Genet Mol Res Gmr, 15(1)Google Scholar
- 22.Hu F, Zhang Y, Li M, Zhao L, Chen J, Yang S et al (2015) Bmp-6 inhibits the metastasis of mda-mb-231 breast cancer cells by regulating mmp-1 expression. Oncol Rep 35(3)Google Scholar
- 25.Shyr CR, Tsai MY, Yeh S, Kang HY, Chang YC, Wong PL et al (2010) Tumor suppressor pax6 functions as androgen receptor co-repressor to inhibit prostate cancer growth. Prostate 70(2):190–199Google Scholar